English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Simple Summary  Diarrhea is common problem for young calves. It causes economic losses to cattle producers because for a newborn calf, diarrhea can be fatal. For this reason, calf diarrhea is an expensive disorder, often requiring prolonged medical treatment. Furthermore, treatment often requires use of drugs and antibiotics, increasing public concerns of excessive usage of drugs in dairy farming, and the development of antibiotic resistance. Therefore, prevention remains the best option, and the preventative strategies against newborn diarrhea aim to increase the immunity and the gut health status early after birth. One common prophylactic strategy against diarrhea is the use health-enhancing supplements in the feed. Our hypothesis is that a combination of different origins and mechanisms of action (lactic acid bacteria as an antimicrobial agent and arabibogalactan as a prebiotic for good microbiota stabilization), can lead to improvement in newborn calves’ health parameters. In this study, the lactic acid bacteria strain, LUHS245, effectively inhibited the growth of pathogenic bacteria, as well being non-resistant to all the tested antibiotics. LUHS245, arabinogalactan, and its combination used for newborn calf feeding showed a desirable positive effect on newborn calf health parameters and it can be recommended in dairy farms for diarrhea prophylaxis.    Abstract  In this study, arabinogalactan (ARB) and  Lactobacillus uvarum  LUHS245 antimicrobial properties against pathogenic bacteria ( Klebsiella pneumoniae, Pseudomonas aeruginosa  17-331,  Acinetobacter baumanni  17-380,  Proteus mirabilis , MRSA M87fox,  Enterococcus faecalis  86,  Enterococcus faecium  103,  Bacillus cereus  18 01, and  Streptococcus mutans ) and resistance to antibiotics were evaluated and the role of their supplementation on the main metabolic and fecal variables of newborn calves was established. The animal trial involved 48 Holstein female calves randomly allocated in four homogeneous groups of 12 animals each, on the basis of body weight in the second day of life. Calves were fed with a standard milk replacer diet from the second day of life until 14th day, either unsupplemented or supplemented with 50 mL of LUHS245 (≥7.5 log 10  CFU mL −1 ), 30 g of ARB, or with both (50 mL of LUHS245 and 30 g ARB). In vitro data showed that the LUHS245 inhibited the growth of  Salmonella enterica  and  Bacillus cereus  (inhibition zones 13.0 and 21.3 mm, respectively). Supplementation of LUHS245 and ARB either alone or together, lowered total bacterial count in the feces and reduced lactate and serum alanine aminotransferase concentrations in blood. This study showed that LUHS245 supplementation alone or together with ARB seemed to have some positive influence on certain health parameters in newborn calves. Further research with larger cohorts of animals is warranted to validate the beneficial effects of the tested supplements.

animals

Separate and Synergic Effects of Lactobacillus uvarum LUHSS245 and Arabinogalactan on the In Vitro Antimicrobial Properties as Well as on the Fecal and Metabolic Profile of Newborn Calves